Groupe d'Etude en Oncologie du Quebec

Titre	This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention
Protocole ID	2023-11332
ClinicalTrials.gov ID	NCT05805319
Type(s) de cancer	Poumon non à petites cellules
Phase	Autres
Type étude	Support
Médicament	Intervention concernant la diète alimentaire
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dr Bertrand Routy
Coordonnateur(trice)	Wiam Belkaid 514-890-8000
Statut	Actif en recrutement
Date d'activation	07-05-2024
Critètes d'éligibilité	Signed, informed consent Age 18 years or older Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI Ability to eat solid foods
Critètes d'exclusion	Severe dietary allergies (e.g. shellfish, nuts, seafood) Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Groupe d'étude en oncologie du Québec